Fed. Circ. Clarifies But Won't Redo AIA On-Sale Bar Ruling

Law360, New York (January 16, 2018, 9:39 PM EST) -- The Federal Circuit on Tuesday said it won’t reconsider invalidating four Helsinn Healthcare SA nausea drug patents in a ruling over the scope of the America Invents Act's on-sale bar, but clarified that its decision isn’t as extreme as the intellectual property world feared.

The case before the Federal Circuit involves four patents that Helsinn alleged Teva infringed with its planned generic version of the anti-nausea drug Aloxi. (Law360) In an opinion concurring with the rehearing denial, U.S. Circuit Judge Kathleen O’Malley broke down what she...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.


Case Number

16-1284

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

December 4, 2015

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.